Relay Therapeutics Inc
RLAYHealthcare|Biotechnology|USA
$20.00
-0.74 (-3.59%)
Tangible Book
$3.39
Earnings Power
$3247.43
Upcoming Data Readouts (4)
Apr 2027
Est. completion
P1PIK3CA Mutation
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432n=930
Dec 2027
Est. completion
P1Advanced NRAS-Mutant Melanoma
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226n=35
Apr 2028
Est. completion
P3PIK3CA Mutation
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521n=540
Jul 2031
Est. completion
P2PIK3CA-Related Overgrowth Spectrum (PROS)
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913n=277